Oxandrolone is one of 94 small molecule programs targeting Facioscapulohumeral dystrophy. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
139 competitors in Trial
Opdivo
Yervoy
Vectibix
Camptosar
Eloxatin
Perjeta
Platinol
Tarceva
Herceptin
Xeloda
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details